hydroxychloroquine has been researched along with Chronic Fatigue and Immune Dysfunction Syndrome in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The diagnosis is mainly serological." | 2.45 | [Q fever: current diagnosis and treatment options]. ( Lepidi, H; Million, M; Raoult, D, 2009) |
| "Moreover, PTSD in patients with COVID-19 is not associated with the increased risk of CFS." | 1.62 | Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. ( Aalipour, MA; Darazam, IA; Ghorbani, F; Pakdaman, H; Ramezani, M; Sagharichi, M; Simani, L, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Simani, L | 1 |
| Ramezani, M | 1 |
| Darazam, IA | 1 |
| Sagharichi, M | 1 |
| Aalipour, MA | 1 |
| Ghorbani, F | 1 |
| Pakdaman, H | 1 |
| Million, M | 1 |
| Lepidi, H | 1 |
| Raoult, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Security of the Magnesium and Vitamin D Combination as Adjuvant Treatment of Post-COVID Syndrome. A Randomised Double-blind Clinical Trial[NCT05630339] | 150 participants (Actual) | Interventional | 2022-01-30 | Completed | |||
| Neuropsychological Sequelae as a Risk Factor for Long COVID-19 Fatigue[NCT05323318] | 200 participants (Anticipated) | Observational | 2022-04-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydroxychloroquine and Chronic Fatigue and Immune Dysfunction Syndrome
| Article | Year |
|---|---|
[Q fever: current diagnosis and treatment options].
Topics: Animals; Coxiella burnetii; Diagnosis, Differential; Doxycycline; Fatigue Syndrome, Chronic; Humans; | 2009 |
1 other study available for hydroxychloroquine and Chronic Fatigue and Immune Dysfunction Syndrome
| Article | Year |
|---|---|
Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Topics: Adult; Aged; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; Dementia; Drug Combinations | 2021 |
Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Topics: Adult; Aged; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; Dementia; Drug Combinations | 2021 |
Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Topics: Adult; Aged; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; Dementia; Drug Combinations | 2021 |
Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Topics: Adult; Aged; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; Dementia; Drug Combinations | 2021 |